search Created with Sketch.
search Created with Sketch.

Advertisement

dermwire-tv-logo Created with Sketch.
dermwire-tv-logo Created with Sketch.

DermWireTV 09.12.19: Otezla to Amgen, A Juvéderm First, Skin Cancer Foundation News

September 10, 2019

After traveling more than 10,000 miles across the US, the Skin Cancer Foundation’s “Destination: Healthy Skin” Program is wrapping up for the season. Plus, the Champions for Change Gala is coming October 17. Amgen has entered into an agreement with Celgene Corporation Company to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities. Allergan’s Juvéderm Voluma XC is now FDA-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. Drs. Andrew Alexis and Richard Rox Anderson honored.

Advertisement

In This Series

View More

Advertisement